Lanas Angel, Muñoz Maria, Caballero Correa Maria, Martínez Jiménez Pedro
Servicio de Aparato Digestivo, Hospital Clínico Lozano Blesa, CIBERehd, Instituto Aragonés de Ciencias de la Salud, Universidad de Zaragoza, Zaragoza, España.
Gastroenterol Hepatol. 2010 Feb;33(2):80-91. doi: 10.1016/j.gastrohep.2009.09.009. Epub 2009 Nov 22.
Preventive measures in patients treated with nonsteroidal anti-inflammatory drugs (NSAIDS) have been reported to be underused. The aim of the present study was to analyze differences between the indication and prescription of gastroprotection with proton pump inhibitors (PPI) in patients treated with NSAIDS and with risk factors for gastrointestinal complications.
We performed an observational, cross-sectional, multicenter study. Data were gathered retrospectively from medical records and from a questionnaire on risk factors and indication for gastroprotection.
A total of 432 physicians gathered data from 2,160 patients treated with NSAIDs. Nearly all (90.4%) of the patients were prescribed gastroprotection with a PPI. Long-term versus short-term (<1 month) NSAID treatment was associated with gastroprotection (OR=2.37; 95% CI 1.779-3.171). The mean number of risk factors per patient was 2+/-0.16 (range 0-7), and a significant association was found between the number of risk factors and the percentage of patients receiving gastroprotection. Nevertheless, the proportion of patients with risk factors not receiving gastroprotection was 3% for those with a prior history of ulcer and/or gastrointestinal bleeding due to NSAIDS and 7-10% for the remaining factors. Differences were found between the indication for gastroprotection and the gastroprotection prescribed among the various specialties. The specialists prescribing gastroprotection the least were radiotherapy specialists.
These results demonstrate that, in daily clinical practice, differences between the indication and prescription of gastroprotection in patients treated with NSAIDS and with risk factors are small in Spain.
据报道,接受非甾体抗炎药(NSAIDs)治疗的患者的预防措施未得到充分利用。本研究的目的是分析接受NSAIDs治疗且有胃肠道并发症风险因素的患者中,质子泵抑制剂(PPI)胃保护的适应证与处方之间的差异。
我们进行了一项观察性、横断面、多中心研究。数据通过回顾病历以及一份关于风险因素和胃保护适应证的问卷收集。
共有432名医生收集了2160例接受NSAIDs治疗患者的数据。几乎所有(90.4%)患者都被处方了PPI进行胃保护。NSAIDs长期治疗与短期(<1个月)治疗相比,与胃保护相关(OR = 2.37;95% CI 1.779 - 3.171)。每位患者的风险因素平均数为2 ± 0.16(范围0 - 7),并且发现风险因素数量与接受胃保护患者的百分比之间存在显著关联。然而,有NSAIDs引起的溃疡和/或胃肠道出血既往史的患者中,未接受胃保护的风险因素患者比例为3%,其余因素的患者比例为7 - 10%。不同专科之间在胃保护适应证和所开具的胃保护处方方面存在差异。开具胃保护最少的专科是放疗专科。
这些结果表明,在西班牙的日常临床实践中,接受NSAIDs治疗且有风险因素的患者中,胃保护的适应证与处方之间的差异较小。